In accordance with previously reported observations [25], splenic ferroportin protein content was not increased by EPO administration (Figure 1A); this apparent lack of effect of EPO on spleen ferroportin was probably associated with the marked splenomegaly induced by EPO treatment (159 ± 35 mg in EPO group vs. 90 ± 32 mg in controls). Here, SLC40A1 is linked to Splenomegaly.